Mission
We aim at an animal-free drug development. myofarm revolutionizes cardiac tissue engineering by providing the world’s first cloud lab. We aim to empower research scientists with an innovative approach to pre-clinical cardiac efficacy and toxicology testing. By offering human stem cell-derived 3D cardiac tissue that reflects natural physiology, we enable our users to accelerate development speed, de-risk substances at early stages, and significantly reduce the reliance on animal testing.
Our efficacy and safety assays are your advantages
Our measurement platform
Our in vitro platform measurement procedure is non-invasive and non-terminal and enables acute, chronic, and repetitive exposures to substances. It allows to synchronously record the following parameters longitudinally and repetitively on individual specimens for up to several weeks:
Get in touch with us for more information
and become an early access customer!
Team
Mariyam
Gaysaeva, B.Sc.
Lab & quality management
Andreas
Meyer-Borgstädt, MBA
Business development
& finance
Dr.-Ing. Jan Patrick Pietras, MBA
Engineering
& Life Sciences
Dr. rer. nat.
Hendrik Windel
Software, Hardware & Data-Science
Shameer
Sarwar, B.Sc.
Cloud Architect & Data Science
Advisory
Dr. rer. nat.
George Kensah
HEAD OF EXPERIMENTAL RESEARCH
DEPARTMENT OF THORACIC AND CARDIOVASCULAR SURGERY
UNIVERSITY MEDICAL CENTER GOETTINGEN (UMG)
Dr. med. vet.
Eckhard von Keutz
Previous Senior Vice President and Head of Translational Sciences at Bayer Pharmaceuticals
Das Projekt myofarm wird im Rahmen des EXIST-Programms durch das Bundesministerium für Wirtschaft und Klimaschutz und den Europäischen Sozialfonds gefördert.